Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies

Trial Profile

A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2018

At a glance

  • Drugs DCC 2618 (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms INVICTUS
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Jan 2018 According to a Deciphera Pharmaceuticals media release, company expects to report top-line results in 2019 and if successful, this pivotal Phase III study could serve as the basis for a New Drug Application (NDA).
    • 04 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top